Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

ClinicalTrials.gov ID: NCT01508936

Public ClinicalTrials.gov record NCT01508936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma

Study identification

NCT ID
NCT01508936
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
511 participants

Conditions and interventions

Interventions

  • Reslizumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2012
Primary completion
Jul 31, 2013
Completion
Jul 31, 2013
Last update posted
Jun 26, 2016

2012 – 2013

United States locations

U.S. sites
66
U.S. states
31
U.S. cities
61
Facility City State ZIP Site status
Investigational Site 861 Birmingham Alabama
Investigational Site 842 Homewood Alabama
Investigational Site 887 Jasper Alabama
Investigational Site 809 Tucson Arizona
Investigational Site 892 Tucson Arizona
Investigational Site 846 Little Rock Arkansas
Investigational Site 828 Anaheim California
Investigational Site 900 Fresno California
Investigational Site 862 Huntington Beach California
Investigational Site 852 Los Angeles California
Investigational Site 909 Los Angeles California
Investigational Site 864 Newport Beach California
Investigational Site 812 Rancho Mirage California
Investigational Site 808 Riverside California
Investigational Site 804 Sacramento California
Investigational Site 837 Centennial Colorado
Investigational Site 851 Denver Colorado
Investigational Site 832 Wheat Ridge Colorado
Investigational Site 855 Jacksonville Florida
Investigational Site 865 Miami Florida
Investigational Site 881 Miami Florida
Investigational Site 805 Albany Georgia
Investigational Site 870 Stockbridge Georgia
Investigational Site 816 Chicago Illinois
Investigational Site 824 Shiloh Illinois
Investigational Site 883 Evansville Indiana
Investigational Site 878 Fort Wayne Indiana
Investigational Site 820 Lenexa Kansas
Investigational Site 873 Owensboro Kentucky
Investigational Site 801 Lafayette Louisiana
Investigational Site 877 Mandeville Louisiana
Investigational Site 875 White Marsh Maryland
Investigational Site 871 Fall River Massachusetts
Investigational Site 834 North Dartmouth Massachusetts
Investigational Site 889 Troy Michigan
Investigational Site 838 Rolla Missouri
Investigational Site 818 St Louis Missouri
Investigational Site 841 St Louis Missouri
Investigational Site 857 Albuquerque New Mexico
Investigational Site 819 Newburgh New York
Investigational Site 844 Charlotte North Carolina
Investigational Site 845 Middleburg Heights Ohio
Investigational Site 810 Tulsa Oklahoma
Investigational Site 859 Ashland Oregon
Investigational Site 859 Portland Oregon
Investigational Site 854 Jenkintown Pennsylvania
Investigational Site 843 Providence Rhode Island
Investigational Site 802 Florence South Carolina
Investigational Site 814 Orangeburg South Carolina
Investigational Site 821 Spartanburg South Carolina
Investigational Site 829 Spartanburg South Carolina
Investigational Site 850 Knoxville Tennessee
Investigational Site 803 Nashville Tennessee
Investigational Site 880 Dallas Texas
Investigational Site 858 Dickinson Texas
Investigational Site 869 Live Oak Texas
Investigational Site 879 Plano Texas
Investigational Site 847 Salt Lake City Utah
Investigational Site 876 West Jordan Utah
Investigational Site 840 Fairfax Virginia
Investigational Site 836 Richmond Virginia
Investigational Site 867 Seattle Washington
Investigational Site 833 Spokane Washington
Investigational Site 904 Vancouver Washington
Investigational Site 806 Greenfield Wisconsin
Investigational Site 823 La Crosse Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01508936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 26, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01508936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →